-+ 0.00%
-+ 0.00%
-+ 0.00%

Oncodesign Precision Medicine, Navigo Proteins Terminate Radiotheranostic Partnership

MT Newswires·12/30/2025 00:17:37
Listen to the news
12:17 AM EST, 12/30/2025 (MT Newswires) -- Oncodesign Precision Medicine (ALOPM.PA) and Navigo Proteins mutually agreed to end their previously agreed partnership, according to a Monday release. The partnership, signed in May 2024, sought to combine the biopharmaceutical companies' tumor-targeting and identification technologies to develop more effective radiotheranostic agents for the treatment of resistant and metastatic cancers.